← Research library

Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)]

Randomized study in people · 2009

What was studied
30 patients with neurasthenia; 15 per arm
Main finding
Single-blind randomized placebo comparison reported symptom improvement. All active-treatment patients completed; only seven placebo participants completed. Missing values were handled using last observation carried forward.

Treatment completion · 15/15 active group versus 7/15 placebo group

Reported findings and study design

Thirty neurasthenia patients randomized 15/15; 28 days of single-blind treatment plus one-week follow-up.

Population or model 30 patients with neurasthenia; 15 per arm

Results · Previously reviewed journal reproduction; allocation, completion and missing-data methods
MeasureResultComparison, timing and statistics
Treatment completion15/15 active group versus 7/15 placebo group
Missing-outcome handlingLast observation carried forwardDifferential dropout may distort symptom comparisons

Values are from the previously checked article reproduction. Overlap with other 2009 Ladasten reports remains unresolved.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Differential attrition and last-observation-carried-forward analysis can bias estimates.
  • Small single-blind comparison with 28-day treatment and one-week follow-up.
  • No long-term absence-of-dependence conclusion follows.
  • Overlap with related 2009 reports remains unresolved.

Related publications may describe some of the same participants or experiments.

Source details

Journal article reproduction

Original article text reproduced on ResearchGate checked, including randomization and attrition passages; independent statistical reanalysis not performed.

Methods, attrition and selected tables

Sources checked

Citation

Randomized trialFull text available

Neznamov GG, Siuniakov SA, Teleshova SE, Chumakov DV, Reutova MA, Siuniakov TS, Mametova LE, Dorofeeva OA, Grishin SA. Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)] Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 109(5):20-26. PMID 19491814

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards